Researchers Mimic Viral Infection in Colon Cancer Stem Cells
Researchers targeting colorectal cancer stem cells – the root cause of disease, resistance to treatment and relapse – have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection. [Press release from University Health Network discussing online publication in Cell] Press Release|Abstract|Graphical Abstract|Video
Intestinal-Specific Activatable Myb Initiates Colon Tumorigenesis in Mice
Investigators generated the first intestinal-specific, inducible transgenic model; a MybER transgene encoding a tamoxifen-inducible fusion protein between Myb and the estrogen receptor-α ligand-binding domain driven by the intestinal-specific promoter, Gpa33. [Oncogene] Abstract
Enhanced Anti-Colon Cancer Immune Responses with Modified eEF2-Derived Peptides
Scientists indicated that modifications of a segment of peptides from wild type eukaryotic elongation factor-2 (eEF2)-derived immunogenic peptides was able to further enhance its capacity of inducing antigen-specific cytotoxic T lymphocytes against colon cancer cells. [Cancer Lett] Abstract
A Mouse Model of Targeted Musashi1 Expression in Whole Intestinal Epithelium Suggests Regulatory Roles in Cell Cycle and Stemness
The authors generated a mouse model, referred to as v-Msi, overexpressing Musashi1 specifically in the entire intestinal epithelium. Compared with wild type litters, v-Msi1 mice exhibited increased intestinal crypt size accompanied by enhanced proliferation. Comparative transcriptomics by RNA-seq revealed Musashi1’s association with gut stem cell signature, cell cycle, DNA replication and drug metabolism. [Stem Cells] Abstract
The Intestinal Epithelium as Guardian of Gut Barrier Integrity
The authors review recent advances that illustrate the intense and intimate host-microbial interaction at the epithelial level and improve the understanding of the mechanisms that maintain the integrity of the intestinal epithelial barrier. [Cell Microbiol] Abstract|Full Article
Visit our reviews page to see a complete list of reviews in the intestinal cell research field.
INDUSTRY NEWS
Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS
Soligenix, Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShield™. The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield™ as a medical countermeasure for the treatment of gastrointestinal acute radiation syndrome (GI ARS). [Soligenix, Inc.] Press Release
Recruit Top Talent: Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Intestinal Cell News? Click here to submit!
